ESMO 2021: Belzutifan (MK-6482) plus cabozantinib for advanced clear cell RCC
Kidney cancers frequently have mutations in the von Hippel-Lindau (VHL) [...]
Kidney cancers frequently have mutations in the von Hippel-Lindau (VHL) [...]
The FDA has approved a new drug called belzutifan for [...]
The US Food and Drug Administration (FDA) has granted priority [...]
Kidney cancers frequently have mutations in the von Hippel-Lindau (VHL) gene, [...]
In a small phase 2 study presented at the virtual [...]
Von Hippel-Lindau (VHL) disease–associated renal cell carcinoma (RCC) has always [...]